Were great vaccines bad business?

You'd think developing a successful Covid vaccine would be an unmitigated win, from a financial perspective. But it's not necessarily so.

March 25, 2024 Check out STAT+

Sponsored By

Coming this Thursday, STAT is launching Adam's Biotech Scorecard, a weekly, subscriber-only newsletter that will feature Adam Feuerstein's candid analysis of the news, events, and people shifting the worlds of biotech and finance. Sign up now.

Illustration: Christine Kao/STAT; Photos: Getty STAT+ | During the pandemic, were great vaccines bad business? A company-by-company review When doing good also means doing well: Analyzing revenues, stock prices for major Covid vaccine makers Pfizer, BioNTech, Moderna, AstraZeneca, and more. By Matthew Herper SCOTUS' abortion pill mifepristone case is really about the FDA Oral arguments, slated for Tuesday on the use of mifepristone, go beyond reproductive rights, raise issues of second-guessing FDA approval of any drug. By Sarah Owermohle STAT+ | Medicare Advantage insurers pressure Biden administration for bigger payments Budget officials within the White House started reviewing final payment regulations for 2025 Medicare Advantage plans last week. By Bob Herman Mike Reddy for STAT STAT+ | Nvidia says generative AI will revolutionize health care. So did IBM, with Dr. Watson Many doctors and computer scientists fear that the breathless rhetoric about generative AI's powers could lead to yet another letdown. By Casey Ross STAT+ | Patient advocates clash over wisdom of 'approving drugs faster and faster' Accelerated approval has been used to speed drugs to dying patients. But has that come at the expense of better evidence and better drugs? By Jason Mast STAT+ | Novo Nordisk to acquire heart disease-focused Cardior Pharmaceuticals in deal worth $1.1 billion The deal, worth up to $1.1 billion, will expand Novo's presence in cardiovascular medicine, as Novo builds on its Wegovy successes. By Andrew Joseph Adobe Disparities in donor acceptance rates point to need for more equitable heart transplant care JAMA study shows heart transplant team acceptance of offers for Black patients are lower than for white patients, women accepted more often than men. By Deborah Balthazar Opinion: Methadone treatment has been reformed for the better. States shouldn't go back to the old ways The federal government made it easier for people to get and take methadone to fight opioid addiction. Some states are sabotaging that move. By Rebecca Arden Harris and David S. Mandell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser